Couture R, Picard P, Poulat P, Prat A
Department of Physiology, Faculty of Medicine, Université de Montréal, QC, Canada.
Can J Physiol Pharmacol. 1995 Jul;73(7):892-902. doi: 10.1139/y95-123.
The pharmacological characterization of the tachykinin receptors involved in spinal and supraspinal cardiovascular regulation is reviewed in this report. In conscious rats, substance P (SP), neurokinin A (NKA), neurokinin B (NKB), neuropeptide K (NPK), and neuropeptide gamma (NP gamma) were injected either intrathecally (i.t.) or intracerebroventricularly (i.c.v.), and their effects were assessed on mean arterial blood pressure (MAP) and heart rate (HR). Moreover, selective antagonists for NK1 ((+/-)-CP-96045 and RP-67580), NK2 (SR-48968), and NK3 (R-486) receptors were tested against the agonists. I.t. tachykinins elicited dose-dependent increases in MAP and HR (NPK > NP gamma > SP > NKA > NKB). The cardiovascular response to i.t. SP, NPK, and NP gamma was significantly attenuated by the prior i.t. administration of (+/-)-CP-96345 and RP-67580 but not by SR-48968 and R-486. By the i.c.v. route, tachykinins also elicited pressor and tachycardiac responses dose dependently (NPK > NP gamma > SP > NKA > NKB). Senktide and [MePhe7]NKB, two NK3-selective agonists, were slightly more potent than NKB on both parameters. Whereas the cardiovascular response to NPK was largely blocked by (+/-)-CP-96345 and RP-67580, that to SP was reduced by 40-50%. This treatment had no effect on the cardiovascular response to NKA and [MePhe7]NKB. Conversely, SR-48968 reduced by 40-50% the NKA-induced cardiovascular changes without affecting the central mediated effects of NPK, SP, and [MePhe7]NKB. However, when coadministered, RP-67580 and SR-48968 abolished the effects to SP and NKA while leaving untouched those induced by [MePhe7]NKB. Finally, the central effects mediated by [MePhe7]NKB, senktide, and NKB were blocked by R-486. These findings suggest that the i.t. action of tachykinins on the rat cardiovascular system is mediated by a NK1 receptor in the spinal cord, while NK1, NK2, and NK3 receptors are likely involved in the supraspinal (hypothalamus) effects of these neuropeptides. It is also concluded that NPK is a pure and powerful NK1 agonist, in contrast to SP and NKA, which are not selective for NK1 and NK2 receptors, respectively.
本报告综述了参与脊髓和脊髓上心血管调节的速激肽受体的药理学特性。在清醒大鼠中,将P物质(SP)、神经激肽A(NKA)、神经激肽B(NKB)、神经肽K(NPK)和神经肽γ(NPγ)经鞘内(i.t.)或脑室内(i.c.v.)注射,并评估它们对平均动脉血压(MAP)和心率(HR)的影响。此外,还测试了NK1((+/-)-CP-96045和RP-67580)、NK2(SR-48968)和NK3(R-486)受体的选择性拮抗剂对激动剂的作用。鞘内注射速激肽可引起MAP和HR的剂量依赖性增加(NPK>NPγ>SP>NKA>NKB)。预先鞘内注射(+/-)-CP-96345和RP-67580可显著减弱鞘内注射SP、NPK和NPγ引起的心血管反应,但SR-48968和R-486则无此作用。经脑室内途径,速激肽也可引起剂量依赖性的升压和心动过速反应(NPK>NPγ>SP>NKA>NKB)。两种NK3选择性激动剂Senktide和[MePhe7]NKB在这两个参数上的效力略高于NKB。虽然NPK引起的心血管反应在很大程度上被(+/-)-CP-96345和RP-67580阻断,但SP引起的反应降低了40-50%。这种处理对NKA和[MePhe7]NKB引起的心血管反应无影响。相反,SR-48968可使NKA引起的心血管变化降低40-50%,而不影响NPK、SP和[MePhe7]NKB的中枢介导作用。然而,当联合给药时,RP-67580和SR-48968可消除对SP和NKA的作用,而不影响[MePhe7]NKB诱导的作用。最后,R-486可阻断[MePhe7]NKB、Senktide和NKB介导的中枢作用。这些发现表明,速激肽对大鼠心血管系统的鞘内作用由脊髓中的NK1受体介导,而NK1、NK2和NK3受体可能参与这些神经肽的脊髓上(下丘脑)作用。还得出结论,与SP和NKA不同,NPK是一种纯的且强效的NK1激动剂,SP和NKA分别对NK1和NK2受体无选择性。